Publicações científicas

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP)

Sanchez-Salcedo P (1), Berto J [ES] (1), de-Torres JP [ES] (1), Campo A [ES] (1), Alcaide AB [ES] (1), Bastarrika G [ES] (2), Pueyo JC [ES] (2), Villanueva A (2), Echeveste JI [ES] (3), Lozano MD [ES] (3), García-Velloso MJ [ES] (4), Seijo LM (5), García J (6), Torre W [ES] (7), Pajares MJ (8), Pío R (8), Montuenga LM (8), Zulueta JJ (9).
(1) Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España.
(2) Departamento de Radiología, Clínica Universidad de Navarra, Pamplona, España.
(3) Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona, España.
(4) Departamento de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
(5) Departamento de Neumología, IIS - Fundación Jiménez Díaz, CIBERES, Madrid, España.
(6) Departamento de Neumología, Clínica Universidad de Navarra, Madrid, España.
(7) Departamento de Cirugía Torácica, Clínica Universidad de Navarra, Pamplona, España.
(8) Centro de Investigación Médica Aplicada - CIMA, Universidad de Navarra, Pamplona, España.
(9) Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España 

Revisão:Archivos de Bronconeumología

Data: 1/Abr/2015

Área de Cancro de Pulmão Radiología [ES] Pneumologia Cirurgia Torácica [ES] Anatomia Patológica [ES] Medicina Nuclear [ES]

INTRODUCTION AND OBJECTIVES
European experience regarding lung cancer screening using low-dose chest CT (LDCT) is available. However, there is limited data on the Spanish experience in this matter. Our aim is to present the results from the longest ongoing screening program in Spain.

METHODOLOGY
The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) is actively screening participants for lung cancer using LDCT since year 2000 following the IELCAP protocol, including spirometric assessments. Men and women, ≥40 years of age, current or former smokers with a tobacco history of ≥10 pack-years are included. Results are compared to those from other European trials.

RESULTS
A total of 2989 participants were screened until March 2014 (73% male). A median of 2 (IQR 1-3) annual screening rounds were performed. Sixty lung cancers were detected in 53 participants (73% in StageI). Adenocarcinoma was the most frequent.

The lung cancer prevalence and incidence proportion was 1.0% and 1.4%, respectively, with an annual detection rate of 0.41. The estimated 10-year survival rate among individuals with lung cancer was 70%. Chronic obstructive pulmonary disease and emphysema are important lung cancer predictors.

CONCLUSIONS
The experience in Spain's longest lung cancer screening program is comparable to what has been described in the rest of Europe, and confirms the feasibility and efficacy of lung cancer screening using LDCT.

CITAÇÃO DO ARTIGO  Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra